Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score

Morphologic determination of the malignant potential of adrenal pheochromocytoma is a challenging problem in surgical pathology. A multiparameter Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) was recently developed based on a comprehensive study of a single institutional cohort of 100 cases. Assignment of a PASS was proposed to be useful for identifying pheochromocytomas with potential to metastasize, which defines malignancy according to the current World Health Organization terminology. A PASS is derived by evaluating multiple morphologic parameters to obtain a scaled score based on the summed weighted importance of each. Despite the proposal of this system several years ago, few studies have since examined its robustness and, in particular, the potential for observer variation inherent in the interpretation and assessment of these morphologic criteria. We further examined the utility of PASS by reviewing an independent single institutional cohort of adrenal pheochromocytomas as evaluated by 5 multi-institutional pathologists with at least 10 years experience in endocrine pathology. We found significant interobserver and intraobserver variation in assignment of PASS with variable interpretation of the underlying components. We consequently suggest that PASS requires further refinement and validation. We cannot currently recommend its use for clinical prognostication.

[1]  Haifeng Zhao,et al.  Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. , 2006, Urology.

[2]  W. Dinjens,et al.  New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas , 2006, Endocrine pathology.

[3]  C. Larsson,et al.  Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor , 2005, Journal of surgical oncology.

[4]  N. Kimura,et al.  Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors , 2005, Endocrine pathology.

[5]  O. Gimm Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx , 2004, Familial Cancer.

[6]  R. Hinze,et al.  CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas , 2004, Modern Pathology.

[7]  C. Larsson,et al.  KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and Paraganglioma , 2003, Modern Pathology.

[8]  S. Singh,et al.  Flow Cytometric DNA Analysis for Determination of Malignant Potential in Adrenal Pheochromocytoma or Paraganglioma: An Indian Experience , 2003, Annals of Surgical Oncology.

[9]  P. Gattuso,et al.  Differential heparanase-1 expression in malignant and benign pheochromocytomas. , 2002, The Journal of surgical research.

[10]  L. Thompson Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.

[11]  S. Asa,et al.  Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques , 2002, Endocrine pathology.

[12]  A. Khorram-Manesh,et al.  N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma , 2002, Endocrine pathology.

[13]  P. Heikkilä,et al.  Increased Expression of Tenascin in Pheochromocytomas Correlates With Malignancy , 2001, The American journal of surgical pathology.

[14]  L. Layfield,et al.  Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal Pheochromocytomas , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  H. Bruining,et al.  Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? , 2000, The Journal of pathology.

[16]  H. Bruining,et al.  Prognostic value of p53, bcl‐2, and c‐erbB‐2 protein expression in phaeochromocytomas , 1999, The Journal of pathology.

[17]  D. Hauri,et al.  Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.

[18]  M. Demeure,et al.  Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. , 1999, Cancer.

[19]  R. Weyant,et al.  Prognostic markers in pheochromocytoma. , 1998, Human pathology.

[20]  L. Castilla-Guerra,et al.  Expression and prognostic value of c‐erbB‐2 oncogene product in human phaeochromocytomas , 1997, Histopathology.

[21]  M. Friedlander,et al.  Prognostic significance of nuclear DNA content in phaeochromocytoma. , 1991, The Australian and New Zealand journal of surgery.

[22]  S. Steinberg,et al.  Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. , 1990, Human pathology.